New Century Healthcare Holding Co. Ltd. 1518

Three blue-chip dividend stocks sitting in a taxable account hand a portion of every payout straight to the IRS, but the account type holding them changes that math completely. Here is what the numbers actually look like across every tax bracket.

Tecan Group is back in focus after analysts lifted their fair value estimate from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Several firms have adjusted targets between CHF 151 and CHF 240, with some raising price goals without changing ratings. This helps explain the higher fair value used in current models. As you read on, you will see how these shifting targets fit into the wider Tecan Group narrative and what to watch as new updates arrive. Stay...

A gas station attendant and part-time janitor from Vermont quietly accumulated over 95 stocks across five decades, and what his neighbors discovered after his death in 2014 stunned an entire community.

From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash flow that keeps covering the check.

Insurers are adapting to shifting market conditions with aggressive cost-cutting measures.

LEXINGTON, Mass., October 03, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by

Align Technology has seen a sharp reset in investor expectations over the past few years, and the question now is whether the current share price lines up with what its earnings can support. After a long period of adjustment in the orthodontics market and changing sentiment toward growth stories, the stock's earnings power is back in focus. Over the past 5 years, Align Technology has fallen 77.7%, which puts a lot of weight on whether the current earnings justify where the stock trades...

Bond markets are throwing out fresh stress signals, with investors racing toward German Bunds and dumping riskier debt across Europe. That kind of flight to safety can punish cyclical stocks and fragile balance sheets, yet it can also shine a harsh but helpful spotlight on sturdier businesses. This article explores 3 Core European Defensive Equities that are closely exposed to this bond shock and explains why their reactions might matter for your portfolio decisions now. The three stocks...

A profitability ratio will be critical to watch in the upcoming earnings report.

Innovative Industrial Properties and Trulieve Cannabis may be turning things around.

Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why investors should own it.

Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2027 Medicare products with choices designed to support older adults with a wide range of health needs, providing reliable benefits that enable affordability and access to quality care. We are expanding the availability of our Chronic Condition Special Needs Plans, growing our High Value Provider Incentive Program, and continuing to focus on care navigation and support.

Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and Russell 2000 closed the week in the red, underscoring a narrow rally as the quarter turned over. The S&P 500 slipped from its prior week's close despite a strong Friday session. Volatility eased, with the VIX down on the day, while crude oil fell sharply and the 10-year Treasury yield ticked higher. Several companies issued contracts, guidance updates, an

Another potential blockbuster just joined AbbVie's drug portfolio.

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Australia’s inflation rate recently reached 4%, and the Reserve Bank lifted its cash rate target to 4.60%, partly linked to the artificial intelligence boom. Higher funding costs can pressure many sectors. Healthcare groups using AI to improve diagnoses, tailor treatments and run hospitals more efficiently could still attract attention. This article highlights three Australian AI healthcare stocks from our focused screener that investors may want on their watchlist. The three stocks below are...

The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end. PBH is a chroni

In September 2026, GRAIL announced that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the...